Streetbeat News

ALX

Alexander's, Inc.

https://www.alx-inc.com

Industry

REIT - Retail

Alexander's, Inc. is a real estate investment trust which has seven properties in the greater New York City metropolitan area.

Open

211.52

Mkt cap

1.1B

Volume

11K

High

215.00

P/E Ratio

23.04

52-wk high

251.63

Low

211.00

Div yield

0.08

52-wk low

203.00

ALX Oncology Holdings Inc. will present updated results from its Phase 2 ASPEN-06 clinical trial of Evorpacept for HER2-positive gastric cancer at the 2025 ASCO Gastrointestinal Cancers Symposium.

Portfolio Pulse from

December 18, 2024 | 1:15 pm

ALX Resources Corp. has received shareholder approval for its acquisition by Greenridge Exploration Inc. through a court-approved plan of arrangement.

Portfolio Pulse from

December 02, 2024 | 9:30 pm

ALX Oncology has appointed Dr. Alan Sandler as its new Chief Medical Officer. Dr. Sandler brings over 30 years of experience in oncology and drug development, which could enhance ALX's strategic direction and drug development efforts.

Portfolio Pulse from

November 14, 2024 | 1:15 pm

ALX Oncology Holdings Inc. reported its financial results for the third quarter of 2024, highlighting its ongoing efforts in developing cancer therapies that enhance the immune system.

Portfolio Pulse from

November 07, 2024 | 9:15 pm

ALX Resources Corp. has announced the filing and mailing of its management information circular for the upcoming Annual and Special Meeting of Shareholders. The meeting will address the proposed acquisition of ALX by Greenridge Exploration Inc.

Portfolio Pulse from

November 07, 2024 | 12:45 pm

Piper Sandler analyst Alexander Goldfarb maintains an Underweight rating on Alexander's (NYSE:ALX) and lowers the price target from $135 to $125.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 1:21 pm

Alexander's (NYSE: ALX) reported Q2 earnings of $3.31 per share, beating the analyst estimate of $2.67 by 23.97%. However, this is a 6.76% decrease from last year's $3.55 per share. Sales were $53.39 million, down 0.52% from $53.67 million YoY.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 12:47 pm

Piper Sandler analyst Alexander Goldfarb maintains an Underweight rating on Alexander's (NYSE:ALX) and lowers the price target from $145 to $135.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 1:13 pm

Piper Sandler analyst Alexander Goldfarb maintains an Underweight rating on Alexander's (NYSE:ALX) and lowers the price target from $160 to $145.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 1:09 pm

Alexander's (NYSE:ALX) reported a significant increase in its Q1 FFO to $4.98 per share, up 37.19% from $3.63 YoY, with sales rising 15.97% to $61.40M from $52.94M YoY.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:53 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.